{"nctId": "NCT05426746", "briefTitle": "First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100", "overallStatus": "COMPLETED", "startDate": "2022-07-05", "completionDate": "2023-05-18", "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "conditions": ["ARDS, Human"], "interventions": [{"type": "DRUG", "name": "ALT-100", "description": "intravenous infusion of drug substance diluted in 0.9% normal sterile saline", "armGroupLabels": ["ALT-100"]}, {"type": "OTHER", "name": "Normal Saline", "description": "intravenous infusion of placebo (0.9% normal sterile saline)", "armGroupLabels": ["Saline"]}]}
{"nctId": "NCT05938036", "briefTitle": "Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS", "overallStatus": "RECRUITING", "startDate": "2023-12-01", "completionDate": "2025-08-31", "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "conditions": ["Acute Respiratory Distress Syndrome (ARDS)"], "interventions": [{"type": "DRUG", "name": "ALT-100 mAb", "description": "Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.", "armGroupLabels": ["Part A : ALT-100 mAB (Dose Escalation)", "Part B (Dose Expansion) ALT-100 mAb"]}, {"type": "DRUG", "name": "ALT-100 (Placebo)", "description": "Normal saline solution via IV solution", "armGroupLabels": ["Part A Placebo"]}]}
{"nctId": "NCT04426695", "briefTitle": "Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19", "overallStatus": "COMPLETED", "startDate": "2020-06-10", "completionDate": "2021-10-22", "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "conditions": ["COVID-19"], "interventions": [{"type": "DRUG", "name": "REGN10933+REGN10987 combination therapy", "description": "Administered intravenously (IV) single dose", "armGroupLabels": ["High O2 No Mechanical Ventilation", "On Low-Flow Oxygen", "On Mechanical Ventilation", "With COVID-19 symptoms but not requiring supplemental O2"], "otherNames": ["REGN-COV2", "REGEN-COV\u2122", "Ronapreve\u2122", "casirivimab", "imdevimab"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo IV Single Dose", "armGroupLabels": ["High O2 No Mechanical Ventilation", "On Low-Flow Oxygen", "On Mechanical Ventilation", "With COVID-19 symptoms but not requiring supplemental O2"]}]}
{"nctId": "NCT04351243", "briefTitle": "A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)", "overallStatus": "COMPLETED", "startDate": "2020-04-15", "completionDate": "2021-04-01", "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "conditions": ["COVID-19"], "interventions": [{"type": "DRUG", "name": "Gimsilumab", "description": "Gimsilumab is a fully human monoclonal antibody (mAb).", "armGroupLabels": ["Gimsilumab"], "otherNames": ["KIN-1901"]}, {"type": "DRUG", "name": "Placebo", "description": "Normal saline", "armGroupLabels": ["Placebo"]}]}
{"nctId": "NCT04802083", "briefTitle": "COVID-19 Soliris Expanded Access Protocol", "overallStatus": "NO_LONGER_AVAILABLE", "startDate": null, "completionDate": null, "studyType": "EXPANDED_ACCESS", "phases": null, "conditions": ["Covid19"], "interventions": [{"type": "BIOLOGICAL", "name": "Eculizumab", "description": "Eculizumab 900-1200 mg will be administered intravenously.", "otherNames": ["Soliris, monoclonal antibody"]}]}
{"nctId": "NCT06513949", "briefTitle": "Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients", "overallStatus": "NOT_YET_RECRUITING", "startDate": "2025-08", "completionDate": "2027-10", "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "conditions": ["Acute Respiratory Distress Syndrome", "Adult Respiratory Distress Syndrome", "Acute Lung Injury", "Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)"], "interventions": [{"type": "BIOLOGICAL", "name": "Atibuclimab", "description": "monoclonal antibody against human CD14", "armGroupLabels": ["IC14 (atibuclimab)"], "otherNames": ["IC14"]}, {"type": "OTHER", "name": "Placebo", "description": "Sterile normal saline for injection", "armGroupLabels": ["Identical-appearing placebo"]}]}
{"nctId": "NCT04346277", "briefTitle": "Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)", "overallStatus": "NO_LONGER_AVAILABLE", "startDate": null, "completionDate": null, "studyType": "EXPANDED_ACCESS", "phases": null, "conditions": ["COVID", "ARDS, Human", "Ards", "SARS-CoV2"], "interventions": [{"type": "BIOLOGICAL", "name": "IC14, a monoclonal antibody against CD14", "description": "IC14 is a recombinant chimeric anti-human monoclonal antibody directed against human CD14. It recognizes both membrane-bound CD14 and soluble CD14.", "otherNames": ["anti-CD14"]}]}
{"nctId": "NCT05156671", "briefTitle": "Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial", "overallStatus": "TERMINATED", "startDate": "2022-10-06", "completionDate": "2023-11-15", "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "conditions": ["COVID-19"], "interventions": [{"type": "BIOLOGICAL", "name": "Adrecizumab (HAM 8101)", "description": "Drip infusion over 60 minutes.", "armGroupLabels": ["Adrecizumab (HAM 8101)"]}, {"type": "DRUG", "name": "Placebo", "description": "Drip infusion over 60 minutes", "armGroupLabels": ["Placebo/ control substance (NaCl 0.9%)"], "otherNames": ["Saline"]}]}
{"nctId": "NCT04397497", "briefTitle": "Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)", "overallStatus": "UNKNOWN", "startDate": "2020-05-22", "completionDate": "2020-11-22", "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "conditions": ["Covid-19", "Acute Respiratory Failure", "ARDS, Human", "Sars-CoV2", "Viral Pneumonia"], "interventions": [{"type": "DRUG", "name": "Mavrilimumab", "description": "human monoclonal antibody targeting GM-CSF receptor-alpha", "armGroupLabels": ["Mavrilimumab"], "otherNames": ["KPL-301", "CAM-3001"]}, {"type": "DRUG", "name": "Placebo", "description": "matching volume of diluent", "armGroupLabels": ["Placebo"]}]}
{"nctId": "NCT03017547", "briefTitle": "A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome", "overallStatus": "WITHDRAWN", "startDate": "2019-06", "completionDate": "2020-06", "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "conditions": ["Acute Respiratory Distress Syndrome"], "interventions": [{"type": "DRUG", "name": "IC14", "description": "Blocks CD14 signalling which is responsible for disease pathogenesis in ARDS", "armGroupLabels": ["IC14"], "otherNames": ["monoclonal antibody against CD14"]}, {"type": "OTHER", "name": "Placebo", "description": "sterile normal saline for infusion", "armGroupLabels": ["Placebo"]}]}
